Century Therapeutics (IPSC) Free Cash Flow (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Free Cash Flow data on file, last reported at -$25.8 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$25.8 million, up 26.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$95.5 million (up 17.16% YoY), and the FY2025 annual result was -$104.7 million, up 5.05% from the prior year.
• Free Cash Flow slipped to -$25.8 million in Q1 2026 per IPSC's latest filing, from -$15.9 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $83.0 million in Q1 2022 and troughed at -$48.3 million in Q3 2022.
• A 5-year average of -$19.5 million and a median of -$25.8 million in 2026 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow soared 449.38% in 2022, then plunged 2121.22% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$1.2 million in 2022, then sank by 2121.22% to -$27.2 million in 2023, then gained by 10.98% to -$24.2 million in 2024, then soared by 34.2% to -$15.9 million in 2025, then slumped by 62.17% to -$25.8 million in 2026.
• Business Quant data shows IPSC's Free Cash Flow at -$25.8 million in Q1 2026, -$15.9 million in Q4 2025, and -$25.8 million in Q3 2025.